← Human Trials & Peer-Reviewed Studies
Mediterranean Diet, Vitamin D, and Hypercaloric, Hyperproteic Oral Supplements for Treating Sarcopenia in Patients with Heart Failure-A Randomized Clinical Trial.
Plain-language guide to PMID 38201939 (2023): open-label randomized controlled trial of Vitamin D, K2, Magnesium and Zinc, hyperparathyroidism.
Key Facts
- PMID
- 38201939
- Journal
- Nutrients
- Year
- 2023
- Study type
- Randomized Controlled Trial
- Authors
- Herrera-Martínez AD et al. (8 authors)
- DOI
- 10.3390/nu16010110
What This Study Did, in Plain Language
What Was Tested
Researchers studied Vitamin D, K2, Magnesium and Zinc in the context of hyperparathyroidism in this randomized controlled trial publication.
To compare the effect of the Mediterranean diet in combination with hypercaloric, hyperproteic OS in patients with HF.
Why It Was Studied
Thus, appropriate nutritional screening and early nutrition support are highly recommended.
Who Took Part
An open label, controlled clinical study in which patients were randomly assigned to receive a Mediterranean diet (control group) vs. hypercaloric, hyperproteic OS (intervention group) for twenty-four weeks.
Thirty-eight patients were included; epidemiological, clinical, anthropometric, ultrasound (muscle echography of the rectus femoris muscle of the quadriceps and abdominal adipose tissue), and biochemical evaluations were performed.
How the Study Was Run
In design terms this was a randomized and open-label study.
The participants were allocated by chance, so the Vitamin D, K2, Magnesium and Zinc group and the comparison group should start out alike.
Being open-label, the Vitamin D, K2, Magnesium and Zinc study did not mask who received what.
All patients received additional supplementation with vitamin D.
What Was Measured
PubMed files the paper under topics including Vitamin D, Quality of Life, Diet, Mediterranean, Nutrition Assessment, Sarcopenia, Nutritional Status and Vitamins.
Author keywords: LVEF, NT-proBNP, heart failure and oral supplements.
What This Means in Plain Language
The paper is a randomized and open-label study of Vitamin D, K2, Magnesium and Zinc in people with hyperparathyroidism.
The abstract goes on to report its results in about 10 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2023 (Nutrients), a journal based in Switzerland.
More context: the Vitamin D, K2, Magnesium and Zinc compound page, Hyperparathyroidism research.
Our Notes on the Compound
Vitamin D, K2, Magnesium and Zinc: Magnesium is described as required for AMPK to function.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.